Shah, N., Kantarjian, H., Hochhaus, A., Cortes, J. E., Bradley-Garelik, M. B., Zhu, C., & Baccarani, M. (2010). Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up. In Blood (Vol. 116, pp. 206–206). American Society of Hematology. https://doi.org/10.1182/blood.v116.21.206.206

Shah, Neil, Hagop Kantarjian, Andreas Hochhaus, Jorge E. Cortes, M Brigid Bradley-Garelik, Chao Zhu, and Michele Baccarani. “Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up.” In Blood, 116:206–206. American Society of Hematology, 2010. https://doi.org/10.1182/blood.v116.21.206.206.

Shah N, Kantarjian H, Hochhaus A, Cortes JE, Bradley-Garelik MB, Zhu C, et al. Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up. In: Blood. American Society of Hematology; 2010. p. 206–206.

Shah, Neil, et al. “Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up.” Blood, vol. 116, no. 21, American Society of Hematology, 2010, pp. 206–206. Crossref, doi:10.1182/blood.v116.21.206.206.

Shah N, Kantarjian H, Hochhaus A, Cortes JE, Bradley-Garelik MB, Zhu C, Baccarani M. Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up. Blood. American Society of Hematology; 2010. p. 206–206.